Dynavax Technologies Corp (DVAX) shares surged over 5% in Friday's pre-market trading session, following the company's strong fourth-quarter earnings report and positive updates on its vaccine pipeline.

The biotech firm achieved record fourth-quarter and annual revenue for its hepatitis B vaccine, Heplisav-B, with net product sales expected to grow between $305 to $325 million in 2025. Dynavax has increased its market share to 44% in the US adult hepatitis B vaccine market, demonstrating robust commercial execution.

Furthermore, Dynavax made promising progress with its shingles vaccine candidate, Z1018, which showed comparable efficacy to the market leader Shingrix in phase 1 trials, but with improved tolerability. The company is also advancing its plague vaccine program in partnership with the US Department of Defense and expects to achieve significant milestones in its development pipeline this year.